Strengthening the reporting of genetic risk prediction studies: the GRIPS statement

[1]  S. Pocock,et al.  [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. , 2021, Gaceta sanitaria.

[2]  M. Khoury,et al.  Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? , 2010, Circulation. Cardiovascular genetics.

[3]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[4]  J. Ioannidis,et al.  Assessment of claims of improved prediction beyond the Framingham risk score. , 2009, JAMA.

[5]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[6]  P. Royston,et al.  Prognosis and prognostic research: application and impact of prognostic models in clinical practice , 2009, BMJ : British Medical Journal.

[7]  Jan P Vandenbroucke,et al.  STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll? , 2009, Journal of clinical epidemiology.

[8]  F. Harrell,et al.  Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association , 2009, Circulation.

[9]  J. Ioannidis,et al.  STrengthening the REporting of Genetic Association studies (STREGA) – an extension of the STROBE statement , 2009, Genetic epidemiology.

[10]  A. Janssens,et al.  Genome-based prediction of common diseases: methodological considerations for future research , 2009, Genome Medicine.

[11]  J. Ioannidis,et al.  Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement , 2009, European Journal of Epidemiology.

[12]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[13]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[14]  E. Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[15]  S. Pocock,et al.  Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.

[16]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, Annals of Internal Medicine [serial online].

[17]  M. Khoury,et al.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? , 2007, Genetics in Medicine.

[18]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[19]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[20]  J. Ioannidis,et al.  Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. , 2007, Journal of the National Cancer Institute.

[21]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Klotz.  Can clinically localized prostate cancer be managed conservatively? , 2005, Nature Clinical Practice Urology.

[23]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[24]  John P A Ioannidis,et al.  Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.

[25]  Andrew N Freedman,et al.  Cancer risk prediction models: a workshop on development, evaluation, and application. , 2005, Journal of the National Cancer Institute.

[26]  Matthias Egger,et al.  The scandal of poor epidemiological research , 2004, BMJ : British Medical Journal.

[27]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. , 2004, Family practice.

[28]  David Moher,et al.  The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration , 2003, Annals of Internal Medicine [serial online].

[29]  C. Gatsonis,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[30]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[31]  M. Khoury,et al.  The Human Genome Epidemiology Network. , 1998, American journal of epidemiology.

[32]  C. T. Bruns.  This work is licensed under the Creative Commons Attribution-Noncommercial- , 2008 .

[33]  D. Rennie,et al.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. , 2003, Annals of internal medicine.

[34]  John P. A. Ioannidis,et al.  American Journal of Epidemiology Commentary the Emergence of Translational Epidemiology: from Scientific Discovery to Population Health Impact , 2022 .